NCT07483385 Efficacy and Safety of Lusutrombopag After Allogeneic Hematopoietic Stem Cell Transplantation
| NCT ID | NCT07483385 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The General Hospital of Western Theater Command |
| Condition | Patients With Hematologic Disorders After Allogeneic Hematopoietic Stem Cell Transplantation |
| Study Type | INTERVENTIONAL |
| Enrollment | 45 participants |
| Start Date | 2026-01-13 |
| Primary Completion | 2027-01-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 45 participants in total. It began in 2026-01-13 with a primary completion date of 2027-01-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is an investigator-initiated prospective, single-center, open-label clinical trial designed to evaluate the clinical efficacy and safety of Lusutrombopag in promoting platelet remodeling after allogeneic hematopoietic stem cell transplantation in patients with hematologic disorders.
Eligibility Criteria
Inclusion Criteria: Participants must meet the following criteria: 1. The patient signed an informed consent form and voluntarily participated in the study. 2. Patients undergoing HLA haploidentical allogeneic hematopoietic stem cell transplantation; 3. Age ≥18 years, regardless of gender 4. ECOG score 0-2 5. Expected survival ≥3 months 6. No severe impairment of function of major organs Exclusion Criteria: If any of the following criteria are met, the participants must be excluded from this research project: 1\) Patients with known allergy to TPO-RAs; 2) Patients who cannot take oral medication due to gastrointestinal symptoms, altered mental status, etc. during transplantation; 3) Other reasons for exclusion as determined by the investigator. \-
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07483385 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Patients With Hematologic Disorders After Allogeneic Hematopoietic Stem Cell Transplantation. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07483385 currently recruiting?
Yes, NCT07483385 is actively recruiting participants. Contact the research team at 408955783@qq.com for enrollment information.
Where is the NCT07483385 trial being conducted?
This trial is being conducted at Chengdu, China.
Who is sponsoring the NCT07483385 clinical trial?
NCT07483385 is sponsored by The General Hospital of Western Theater Command. The trial plans to enroll 45 participants.